This has been attributed to the heterogeneity found within tumors, antibody affinities, limited specificity, or variations in target epitopes.37 Moreover, the tumor changes dynamically during the course of treatment and a static snapshot by means of a tumor biopsy for the purposes of PD‐L1 assessment may not represent a continuously adapting tumor landscape in response to targeted therapy. The gene discussed is CD274; the disease is neoplasm.